Products
Pre-made Teclistamab benchmark antibody ( Bispecific mAb, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-557
Pre-Made Teclistamab biosimilar, Bispecific mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Teclistamab is an off-the-shelf, T-Cell redirecting, bispecific antibody targeting both BCMA and CD3 receptors. BCMA is expressed at high levels on multiple myeloma cells. 4,5,6,7,8. Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce killing of tumor cells.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-557-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-557-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-557-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-557-xmg | ＞100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Teclistamab biosimilar, Bispecific mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
| INN Name | Teclistamab |
| Target | TNFRSF17;CD3E |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Lambda;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Genmab;Janssen Research & Development |
| Conditions Approved | na |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | na |
| Development Tech | na |
